




The relative strengths and weaknesses of CTI Biopharma CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI Biopharma CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 37% points. The greatest weakness of CTI Biopharma CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 246%, being 3.6% points above the market average of 243%.

| Input Variable                              | Value in<br>1000 USD | Output Variable             | Value in<br>1000 USD |
|---------------------------------------------|----------------------|-----------------------------|----------------------|
| Assets, Current                             | 80,515               | Assets                      | 93,723               |
| Cost of Goods Sold                          | 0                    | Liabilities                 | 37,504               |
| Intangible Assets                           | 0                    | Expenses                    | 76,204               |
| Liabilities, Current                        | 20,069               | Revenues                    | 34,678               |
| Liabilities, Non-Current                    | 15,809               | Stockholders Equity         | 56,219               |
| Other Assets                                | 7,730                | Net Income                  | -43,550              |
| Other Compr. Net Income                     | 651                  | Comprehensive Net Income    | -43,224              |
| Other Expenses                              | 292                  | BaseVar                     | 122,392              |
| Other Liabilities                           | 1,626                | ECR before LimitedLiability | 121%                 |
| Other Net Income                            | -2,024               | Economic Capital Ratio      | 246%                 |
| Other Revenues                              | 34,678               |                             |                      |
| Property and Equipment                      | 5,478                |                             |                      |
| Research and Development                    | 33,624               |                             |                      |
| Selling, General and Administrative Expense | 42,288               |                             |                      |